U.S. flag

An official website of the United States government

Format

Send to:

Choose Destination

Refractory Non-Muscle Invasive Bladder Urothelial Carcinoma

MedGen UID:
1792887
•Concept ID:
C5556446
•
Neoplastic Process
Synonyms: Refractory Non-Muscle Invasive Bladder Transitional Cell Carcinoma; Refractory Superficial Bladder Transitional Cell Carcinoma; Refractory Superficial Bladder Urothelial Carcinoma

Definition

Non-muscle invasive bladder urothelial carcinoma that is resistant to treatment. [from NCI]

Term Hierarchy

CClinical test,  RResearch test,  OOMIM,  GGeneReviews,  VClinVar  
  • CROGVRefractory Non-Muscle Invasive Bladder Urothelial Carcinoma

Professional guidelines

PubMed

Immune checkpoints inhibitors in the management of high-risk non-muscle-invasive bladder cancer. A scoping review.
García-Perdomo HA, Sánchez AL, Spiess PE
Urol Oncol 2022 Sep;40(9):409.e1-409.e8. Epub 2022 Feb 26 doi: 10.1016/j.urolonc.2022.02.003. PMID: 35232680
Anti-Programmed Cell Death 1/Ligand 1 (PD-1/PD-L1) Antibodies for the Treatment of Urothelial Carcinoma: State of the Art and Future Development.
Powles T, Necchi A, Rosen G, Hariharan S, Apolo AB
Clin Genitourin Cancer 2018 Apr;16(2):117-129. Epub 2017 Dec 6 doi: 10.1016/j.clgc.2017.11.002. PMID: 29325739Free PMC Article
EAU guidelines on non-muscle-invasive urothelial carcinoma of the bladder: update 2013.
Babjuk M, Burger M, Zigeuner R, Shariat SF, van Rhijn BW, Compérat E, Sylvester RJ, Kaasinen E, Böhle A, Palou Redorta J, Rouprêt M; European Association of Urology
Eur Urol 2013 Oct;64(4):639-53. Epub 2013 Jun 12 doi: 10.1016/j.eururo.2013.06.003. PMID: 23827737

Recent clinical studies

Etiology

Immune checkpoints inhibitors in the management of high-risk non-muscle-invasive bladder cancer. A scoping review.
García-Perdomo HA, Sánchez AL, Spiess PE
Urol Oncol 2022 Sep;40(9):409.e1-409.e8. Epub 2022 Feb 26 doi: 10.1016/j.urolonc.2022.02.003. PMID: 35232680
Emerging treatments for bacillus Calmette-Guérin-unresponsive non-muscle-invasive bladder cancer.
Kim HS, Seo HK
Investig Clin Urol 2021 Jul;62(4):361-377. Epub 2021 May 27 doi: 10.4111/icu.20200602. PMID: 34085791Free PMC Article
Role of immunotherapy in bladder cancer.
Rhea LP, Mendez-Marti S, Kim D, Aragon-Ching JB
Cancer Treat Res Commun 2021;26:100296. Epub 2020 Dec 24 doi: 10.1016/j.ctarc.2020.100296. PMID: 33421822
EAU Guidelines on Non-Muscle-invasive Urothelial Carcinoma of the Bladder: Update 2016.
Babjuk M, Böhle A, Burger M, Capoun O, Cohen D, Compérat EM, Hernández V, Kaasinen E, Palou J, Rouprêt M, van Rhijn BWG, Shariat SF, Soukup V, Sylvester RJ, Zigeuner R
Eur Urol 2017 Mar;71(3):447-461. Epub 2016 Jun 17 doi: 10.1016/j.eururo.2016.05.041. PMID: 27324428
EAU guidelines on non-muscle-invasive urothelial carcinoma of the bladder: update 2013.
Babjuk M, Burger M, Zigeuner R, Shariat SF, van Rhijn BW, Compérat E, Sylvester RJ, Kaasinen E, Böhle A, Palou Redorta J, Rouprêt M; European Association of Urology
Eur Urol 2013 Oct;64(4):639-53. Epub 2013 Jun 12 doi: 10.1016/j.eururo.2013.06.003. PMID: 23827737

Diagnosis

The prognostic value of expressions of STAT3, PD-L1, and PD-L2 in Ta/T1 urothelial carcinoma before and after BCG treatment.
Civriz AH, Teke K, Akdas EM, Dillioglugil O, Vural C, Yaprak Bayrak B
Urol Oncol 2023 Dec;41(12):486.e1-486.e13. Epub 2023 Sep 9 doi: 10.1016/j.urolonc.2023.08.012. PMID: 37690934
Immune checkpoints inhibitors in the management of high-risk non-muscle-invasive bladder cancer. A scoping review.
García-Perdomo HA, Sánchez AL, Spiess PE
Urol Oncol 2022 Sep;40(9):409.e1-409.e8. Epub 2022 Feb 26 doi: 10.1016/j.urolonc.2022.02.003. PMID: 35232680
Cytological and histological changes in the urothelium produced by electromotive drug administration (EMDA) and by the combination of intravescical hyperthermia and chemotherapy (thermochemotherapy).
Pierconti F, Straccia P, Emilio S, Bassi PF, De Pascalis I, Marques RC, Volavsek M, Larocca LM, Lopez-Beltran A
Pathol Res Pract 2017 Sep;213(9):1078-1081. Epub 2017 Aug 1 doi: 10.1016/j.prp.2017.07.026. PMID: 28843746
EAU Guidelines on Non-Muscle-invasive Urothelial Carcinoma of the Bladder: Update 2016.
Babjuk M, Böhle A, Burger M, Capoun O, Cohen D, Compérat EM, Hernández V, Kaasinen E, Palou J, Rouprêt M, van Rhijn BWG, Shariat SF, Soukup V, Sylvester RJ, Zigeuner R
Eur Urol 2017 Mar;71(3):447-461. Epub 2016 Jun 17 doi: 10.1016/j.eururo.2016.05.041. PMID: 27324428
EAU guidelines on non-muscle-invasive urothelial carcinoma of the bladder: update 2013.
Babjuk M, Burger M, Zigeuner R, Shariat SF, van Rhijn BW, Compérat E, Sylvester RJ, Kaasinen E, Böhle A, Palou Redorta J, Rouprêt M; European Association of Urology
Eur Urol 2013 Oct;64(4):639-53. Epub 2013 Jun 12 doi: 10.1016/j.eururo.2013.06.003. PMID: 23827737

Therapy

Role of immunotherapy in bladder cancer.
Rhea LP, Mendez-Marti S, Kim D, Aragon-Ching JB
Cancer Treat Res Commun 2021;26:100296. Epub 2020 Dec 24 doi: 10.1016/j.ctarc.2020.100296. PMID: 33421822
Antibody-Drug Conjugates in Urothelial Carcinomas.
Sarfaty M, Rosenberg JE
Curr Oncol Rep 2020 Feb 1;22(2):13. doi: 10.1007/s11912-020-0879-y. PMID: 32008109
Current clinical trials in non-muscle invasive bladder cancer.
Siddiqui MR, Grant C, Sanford T, Agarwal PK
Urol Oncol 2017 Aug;35(8):516-527. doi: 10.1016/j.urolonc.2017.06.043. PMID: 28778250Free PMC Article
Valrubicin in refractory non-muscle invasive bladder cancer.
Sharma P, Zargar-Shoshtari K, Sexton WJ
Expert Rev Anticancer Ther 2015;15(12):1379-87. Epub 2015 Nov 16 doi: 10.1586/14737140.2015.1115350. PMID: 26569509
EAU guidelines on non-muscle-invasive urothelial carcinoma of the bladder: update 2013.
Babjuk M, Burger M, Zigeuner R, Shariat SF, van Rhijn BW, Compérat E, Sylvester RJ, Kaasinen E, Böhle A, Palou Redorta J, Rouprêt M; European Association of Urology
Eur Urol 2013 Oct;64(4):639-53. Epub 2013 Jun 12 doi: 10.1016/j.eururo.2013.06.003. PMID: 23827737

Prognosis

Predictive and Prognostic Biomarkers and Tumor Antigens for Targeted Therapy in Urothelial Carcinoma.
Eturi A, Bhasin A, Zarrabi KK, Tester WJ
Molecules 2024 Apr 22;29(8) doi: 10.3390/molecules29081896. PMID: 38675715Free PMC Article
Anti-Programmed Cell Death 1/Ligand 1 (PD-1/PD-L1) Antibodies for the Treatment of Urothelial Carcinoma: State of the Art and Future Development.
Powles T, Necchi A, Rosen G, Hariharan S, Apolo AB
Clin Genitourin Cancer 2018 Apr;16(2):117-129. Epub 2017 Dec 6 doi: 10.1016/j.clgc.2017.11.002. PMID: 29325739Free PMC Article
Prospects and progress of immunotherapy for bladder cancer.
Boegemann M, Aydin AM, Bagrodia A, Krabbe LM
Expert Opin Biol Ther 2017 Nov;17(11):1417-1431. Epub 2017 Aug 23 doi: 10.1080/14712598.2017.1366445. PMID: 28832261
EAU Guidelines on Non-Muscle-invasive Urothelial Carcinoma of the Bladder: Update 2016.
Babjuk M, Böhle A, Burger M, Capoun O, Cohen D, Compérat EM, Hernández V, Kaasinen E, Palou J, Rouprêt M, van Rhijn BWG, Shariat SF, Soukup V, Sylvester RJ, Zigeuner R
Eur Urol 2017 Mar;71(3):447-461. Epub 2016 Jun 17 doi: 10.1016/j.eururo.2016.05.041. PMID: 27324428
EAU guidelines on non-muscle-invasive urothelial carcinoma of the bladder: update 2013.
Babjuk M, Burger M, Zigeuner R, Shariat SF, van Rhijn BW, Compérat E, Sylvester RJ, Kaasinen E, Böhle A, Palou Redorta J, Rouprêt M; European Association of Urology
Eur Urol 2013 Oct;64(4):639-53. Epub 2013 Jun 12 doi: 10.1016/j.eururo.2013.06.003. PMID: 23827737

Clinical prediction guides

Predictive and Prognostic Biomarkers and Tumor Antigens for Targeted Therapy in Urothelial Carcinoma.
Eturi A, Bhasin A, Zarrabi KK, Tester WJ
Molecules 2024 Apr 22;29(8) doi: 10.3390/molecules29081896. PMID: 38675715Free PMC Article
The emerging role of antibody-drug conjugates in urothelial carcinoma.
Lattanzi M, Rosenberg JE
Expert Rev Anticancer Ther 2020 Jul;20(7):551-561. Epub 2020 Jul 21 doi: 10.1080/14737140.2020.1782201. PMID: 32552213Free PMC Article
Prospects and progress of immunotherapy for bladder cancer.
Boegemann M, Aydin AM, Bagrodia A, Krabbe LM
Expert Opin Biol Ther 2017 Nov;17(11):1417-1431. Epub 2017 Aug 23 doi: 10.1080/14712598.2017.1366445. PMID: 28832261
EAU Guidelines on Non-Muscle-invasive Urothelial Carcinoma of the Bladder: Update 2016.
Babjuk M, Böhle A, Burger M, Capoun O, Cohen D, Compérat EM, Hernández V, Kaasinen E, Palou J, Rouprêt M, van Rhijn BWG, Shariat SF, Soukup V, Sylvester RJ, Zigeuner R
Eur Urol 2017 Mar;71(3):447-461. Epub 2016 Jun 17 doi: 10.1016/j.eururo.2016.05.041. PMID: 27324428
EAU guidelines on non-muscle-invasive urothelial carcinoma of the bladder: update 2013.
Babjuk M, Burger M, Zigeuner R, Shariat SF, van Rhijn BW, Compérat E, Sylvester RJ, Kaasinen E, Böhle A, Palou Redorta J, Rouprêt M; European Association of Urology
Eur Urol 2013 Oct;64(4):639-53. Epub 2013 Jun 12 doi: 10.1016/j.eururo.2013.06.003. PMID: 23827737

Recent systematic reviews

Extended versus standard lymph node dissection for urothelial carcinoma of the bladder in patients undergoing radical cystectomy.
Hwang EC, Sathianathen NJ, Imamura M, Kuntz GM, Risk MC, Dahm P
Cochrane Database Syst Rev 2019 May 14;5(5):CD013336. doi: 10.1002/14651858.CD013336. PMID: 31111956Free PMC Article

Supplemental Content

Table of contents

    Practice guidelines

    • PubMed
      See practice and clinical guidelines in PubMed. The search results may include broader topics and may not capture all published guidelines. See the FAQ for details.
    • Bookshelf
      See practice and clinical guidelines in NCBI Bookshelf. The search results may include broader topics and may not capture all published guidelines. See the FAQ for details.

    Related information

    • PubMed
      Related literature resources in PubMed

    Recent activity

    Clear Turn Off Turn On

    Your browsing activity is empty.

    Activity recording is turned off.

    Turn recording back on

    See more...